FibroBiologics, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company’s pipeline includes product candidates such as CYWC628, CYMS101, CYPS317, and CybroCell, which are being developed to address areas of significant unmet medical need. FibroBiologics also works with fibroblast cells and fibroblast-derived materials in research programs related to tissue regeneration and immune modulation. Based in Houston, Texas, FibroBiologics plays a specialized role in the biotechnology market by advancing cell-based approaches designed for therapeutic use across several disease areas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Peter O'Heeron
- Employees
- 13
- Headquarters
- Houston, TX, United States
- Website
- www.fibrobiologics.com